Gbola Amusa, MD, MBA, CFA

Partner and Chief Scientific Officer, Chardan

Gbola Amusa, MD, MBA, CFA

Partner and Chief Scientific Officer, Chardan

Dr.Working within the Chardan Investment Banking Division, Gbola Amusa, MD, MBA, CFA, is responsible for advising disruptive health care companies on capital formation strategies, mergers and acquisitions, and other transactions. Dr. Amusa joined Chardan at the end of 2014 to focus on identifying companies that will generate exceptionally high long-term investment returns from creating and sharing in real value for society. While in the Chardan Equity Research Department from 2014 through July 2021, Dr. Amusa’s coverage, top picks and counter-consensus calls were all associated with exceptional alpha generation. In a 2019 study by TipRanks, Dr. Amusa was ranked second out of more than 6,000 Wall Street analysts for his stock-picking performance.

Dr. Amusa was previously managing director, head of European Pharma Research, and Global Pharma & Biotech coordinator at UBS Wealth Management USA, where he oversaw 25 analysts and was the top ranked European pharma analyst in the Institutional Investor (II) Survey. Prior to UBS, Dr. Amusa was a senior research analyst and head of European Pharma research at Sanford C. Bernstein & Co. He started his career in finance at Goldman Sachs as an associate in the Healthcare Investment Banking Group, where he worked on large transactions including the Amgen/Immunex merger. Additionally, Dr. Amusa was previously a healthcare finance and strategy consultant working with governments, companies, leading foundations and think tanks. Dr. Amusa’s views on health care have been cited for socially responsible investing (SRI) and environmental, social and corporate governance (ESG) by sustainability organizations like the Foundation Strategy Group’s (FSG) Shared Value Initiative, GMI Ratings and the AtM Index.

Dr. Amusa earned a BSE with honors in biomedical engineering from Duke University, an MD from Washington University Medical School and an MBA (GPA 4.0/4.0) from the University of Chicago, Booth School of Business. He currently serves on the board of directors for BiomX and Renovacor. He has been published in Human Gene Therapy Clinical Development.